ABBVIE

The "Relapsed Multiple Myeloma - Global Clinical Trials Review, 2024" report offers an overview of clinical trials worldwide, detailing trials by region, country, phase, status, and sponsor type, including prominent drugs and companies involved.

The Genital Warts market, valued at ~USD 860M in 2023, is expected to grow significantly by 2034 due to increasing prevalence and awareness. Key companies include Medicis Pharmaceuticals and Novartis, with therapies like Imiquimod and Veregen. In 2023, 860,000 cases were reported across 7MM, with the US leading at 547,000. The market anticipates major changes with emerging therapies and pipeline products.

Atogepant, a new oral medication, offers rapid migraine relief potentially from day one, outperforming traditional treatments requiring weeks for effect. Clinical trials show significant improvements in migraine frequency and quality of life, with mild side effects.

Qulipta, a new migraine medication, shows effectiveness from the first day, reducing migraine risk by 37% to 61% in clinical trials. Approved by the FDA in 2021, it blocks CGRP, a protein involved in migraines, offering quick relief and improved quality of life for patients.

The breast cancer drugs market is rapidly expanding, driven by targeted therapies for HER2-positive cancers. The global market, valued at USD 32.93 billion in 2023, is projected to reach USD 78.61 billion by 2033. North America leads with a 38.61% revenue share. Key players include Oncolytics Biotech, GSK, AstraZeneca, AbbVie, and Cardiff Oncology.

FDA-approved biosimilars for IBD and inflammatory diseases, launching in 2025, aim to improve access, reduce costs, and expand treatment options.

The report on the Antibiotic Resistance Therapeutics Market 2025-2029 highlights over 100 biotech companies, focusing on new technologies and drugs to combat antimicrobial resistance and superbugs. It identifies six key market opportunities and emphasizes the role of diagnostics in treatment strategies.

The report on the Antibiotic Resistance Therapeutics Market 2025-2029 highlights over 100 biotech companies, new technologies against antimicrobial resistance, and identifies six key market opportunities, emphasizing the role of diagnostics.

The Cancer Immunotherapy Market 2025-2029 report forecasts significant growth in immuno-oncology therapeutics, highlighting technologies like CAR-T Cells and Checkpoint Inhibitors. It offers insights into market opportunities, key players, and the impact on healthcare, aiming to guide investment and strategic decisions.